Physician profile
Grace A Haynes
NPI 1215070792
$2,205.23
in general payments reported to CMS, 2019-2025
22 companies · $17.62 in 2025
The $17.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $232 · 2021: $1,691 · 2024: $83.79 · 2025: $17.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,238.84 | 2021 | |
| Novo Nordisk INC | $115.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $107.72 | 2019-2021 | |
| Lilly USA, LLC | $98.22 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.36 | 2019-2021 | |
| Abbvie INC. | $66.04 | 2021 | |
| Embecta Corp. | $65.88 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Amgen INC. | $61.32 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.61 | 2021 | |
| Radius Health, INC. | $44.39 | 2021 | |
| Antares Pharma, INC. | $42.90 | 2019-2020 | |
| Gilead Sciences, INC. | $36.34 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $31.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $28.25 | 2019-2020 | |
| Allergan, INC. | $19.38 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.91 | 2024 | Proclaim |
| Exact Sciences Corporation | $17.62 | 2025 | The Cologuard Plus Collection Kit |
| Collegium Pharmaceutical, INC. | $15.13 | 2021 | |
| Eisai INC. | $13.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.